Tigecycline for Treatment of Rapidly Growing Mycobacteria

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center at Tyler
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Minocycline; Tigecycline

Criteria

Inclusion Criteria:

• Positive cultures for rapidly growing mycobacteria

• Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs

• Adults and children 10 years of age and older

• Pretreatment isolate of M. avium complex available for MIC determination

• Available for followup appointments

Exclusion Criteria:

• History of tetracycline allergy

• If a menstruating female, not pregnant and on adequate birth control